Welcome to the first European Bank for induced pluripotent Stem Cells (EBiSC)

 

 

EBiSC has been designed to address the increasing demand for quality-controlled, disease-relevant, research-grade iPSC lines, data and cell services.

EBiSC is a centralised, not-for-profit iPSC bank providing researchers across academia and industry with access to scalable, cost-efficient and consistent, high quality tools for new medicines development.

EBiSC has established a robust, reliable supply chain from the generation of cell lines, over the specification, to internationally accepted quality criteria and their world-wide distribution to any qualified user.

EBiSC has been developed within a large European public-private partnership project coordinated by Janssen Pharmaceutica and managed by Roslin Cells Sciences Ltd. and which was supported jointly between 2014-2017 by the Innovative Medicines Initiative (IMI) and members of the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Read more about the EBiSC project »

  

 

 

 

 

NEW on 1st March 2019:

EBiSC2 – The European Bank for induced pluripotent Stem Cells launches a second project phase to become a self-sustainable repository for human induced pluripotent stem cells (hiPSC), extend the existing cell catalogue, and offer additional hiPSC-related services.

EBiSC2 will secure long-term access to well characterised and quality-controlled hiPSCs for academic and commercial researchers worldwide, continuing to support R&D activities such as disease modelling and drug discovery.

 Read the full EBiSC2 Press Release

 

 

   
     

 

EBiSC is a large European public-private partnership project coordinated by Pfizer Ltd and managed by Roslin Cells Siences Ltd. and supported jointly by the Innovative Medicines Initiative (IMI) and members of the European Federation of Pharmaceutical Industries and Associations (EFPIA).##FROM_INSIDE_TINYMCE##
Follow us on Twitter Follow us on LinkedIn